Previous close | 14.17 |
Open | 14.01 |
Bid | 14.08 x 3200 |
Ask | 14.09 x 3000 |
Day's range | 14.01 - 14.12 |
52-week range | 13.19 - 17.15 |
Volume | |
Avg. volume | 1,871,853 |
Market cap | 44.178B |
Beta (5Y monthly) | 0.64 |
PE ratio (TTM) | 34.31 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.66 (4.23%) |
Ex-dividend date | 29 Sept 2022 |
1y target est | N/A |
OSAKA, Japan & CAMBRIDGE, Mass., November 27, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego. Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases.
OSAKA, Japan & CAMBRIDGE, Mass., November 09, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). ADZYNMA is the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein designed to address an unmet medical need in people with cTTP by replacing the defici
OSAKA, Japan & CAMBRIDGE, Mass., November 08, 2023--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is the first and only selective